[Drug metabolism in patients with liver disease (author's transl)].

Abstract

Patients with acute hepatitis and patients with compensated or decompensated cirrhosis of the liver have a decreased plasma clearance of hexobarbital. This however could not been demonstrated in patients with intra- or extrahepatic cholestasis and patients with primary biliary cirrhosis of the liver. The plasma clearance of methohexital, - a high clearance drug - is not changed in the same way. Also there is no evidence as yet, that patients with liver disease and without a collateral portal circulation do have an increased bioavailability of oral high clearance drugs.

• Authors: E Richter, J Epping, M Fuchshofen-Röckel, H Heusler, W Zilly
• Journal: Leber, Magen, Darm (Leber Magen Darm) Vol. 10 Issue 5 Pg. 234-40 (Oct 1980) ISSN: 0300-8622 [Print] Germany
• Vernacular Title: Arzneimittelmetabolismus bei Patienten mit Lebererkrankungen.
• PMID: 7464410 (Publication Type: English Abstract, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Lidocaine
• Hexobarbital
• Methohexital
• Antipyrine

Topics

• Acute Disease
• Adult
• Antipyrine (metabolism)
• Biological Availability
• Biotransformation
• Cholestasis (metabolism)
• Female
• Hepatitis (metabolism)
• Hexobarbital (metabolism)
• Humans
• Lidocaine (metabolism)
• Liver Cirrhosis (metabolism)
• Liver Diseases (metabolism)
• Male
• Methohexital (metabolism)
• Middle Aged